<p>New Delhi: Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.</p>.<p>The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing.</p>.<p>Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.</p>.<p>Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas.</p>.Daikin, Voltas, other electronics giants sue Indian government over e-waste policy.<p>The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said.</p>.<p>Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE. </p>
<p>New Delhi: Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.</p>.<p>The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing.</p>.<p>Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.</p>.<p>Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas.</p>.Daikin, Voltas, other electronics giants sue Indian government over e-waste policy.<p>The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said.</p>.<p>Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE. </p>